China is striving to become the global leader in biopharmaceuticals, but many of its policy steps are “innovation mercantilist” in nature. This not only is expected to threaten U.S. leadership, but also slow global life sciences innovation, with negative consequences for cures and treatments.
March 17, 2014
What if innovation in life sciences stopped? A new study on Swedish healthcare provides insight.
March 14, 2014
The Potentially Deleterious Impacts of the President’s FY 2015 Budget on U.S. Life Sciences Industries
The President's FY 2015 budget should do more to promote the innovation capacity and competitiveness of U.S. life sciences industries.
December 1, 2013
The TPP will only be worth it if it concludes with an innovation-maximizing trade agreement that sets the standard for future trade deals for the U.S.
July 8, 2013
Better use of data analytics can help us make better predictions and fewer errors.
December 5, 2012
Further evidence that debunks the myth that pharmaceutical companies aren't providing real value to the economy.
October 2, 2012
Rob Atkinson will present at FTC workshop "Competition & Consumer Protection Issues in the Pet Medications Industry"
September 12, 2012
Non-partisan report evaluates the candidates' positions on innovation-based policy.
September 5, 2012
As the 2012 presidential campaign moves in the final stage, ITIF is presenting general principles and specific recommendations across several policy areas.
August 28, 2012
Negotiations toward the TPP Agreement should conclude with a gold-standard trade agreement.
July 23, 2012
Pharmaceutical proliferation leads to longer, wealthier lives.